Skip to main content

Table 3 Baseline characteristics of the ISS T-002 study participants by treatment groups

From: HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial

 

Tat 7.5 μg, 3x

Tat 7.5 μg, 5x

Tat 30 μg, 3x

Tat 30 μg, 5x

( n  = 40)

( n  = 40)

( n  = 38)

( n  = 37)

Age

    

Mean ± s.d.a

40 ± 7

41 ± 6

43 ± 5

42 ± 8

Range

24-54

29-55

33-55

26-54

Gender

    

Male

73%

90%

79%

92%

Female

27%

10%

21%

8%

CD4 + nadir (cells/μl)

    

Mean ± s.d.

287 ± 74

321 ± 139

337 ± 165

285 ± 136

Range

97-450

76-699

15-846

14-585

CD4 + (cells/μl)

    

Mean ± s.d.

660 ± 216

644 ± 233

617 ± 214

632 ± 222

Range

293-1490

214-1382

212-1362

286-1250

CD4 + (%)

    

Mean ± s.d.

34 ± 7

33 ± 7

33 ± 7

33 ± 10

Range

22-53

20-46

19-47

14-61

Years from diagnosis of HIV

    

Mean ± s.d.

8 ± 6

10 ± 6

10 ± 7

9 ± 7

Range

1-21

2-25

1-23

1-24

Years from HAART initiation

    

Mean ± s.d.

5 ± 4

6 ± 4

7 ± 5

7 ± 5

Range

0-19

0-19

0-18

1-17

Current HAART regimen

    

NNRTI-based or NRTI

58%

75%

66%

76%

PI-based

42%

25%

34%

24%

  1. n indicates the number of evaluable individuals; aStandard deviation.
  2. No significant differences were detected among treatment groups at baseline.